Zoetis Investors Face Class Action Lawsuit Over Alleged Market Misleading

The complaint alleges that Zoetis masked significant commercial struggles during the class period, specifically citing a decline in veterinarian prescriptions for its Librela medication following FDA safety warnings about neurological complications in dogs. Furthermore, the filing claims the company lost ground as its Trio product and dermatology staples, Apoquel and Cytopoint, faced increasing pressure from newly launched market competitors. Shareholders who suffered losses due to these discrepancies have until July 27, 2026, to contact the firm for potential lead plaintiff status. Brian Schall of The Schall Law Firm is overseeing the inquiry, which remains open to those impacted by the company's public disclosures during the specified timeframe. While the class has not yet been certified, investors are advised that remaining inactive will leave them as absent class members in the ongoing securities litigation.